$RLFTF DD "opinion" post by Ingelr - Key takeaways from

New Post Public Reply Private Reply Replies (0) Message Board
mc67
495
$RLFTF DD "opinion" post by Ingelr - Key takeaways from Phase 2b/3 trial Initial Data Release


NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

RADNOR, Pa. and GENEVA, Feb. 9, 2021 /PRNewswire/ -- NeuroRx, Inc.. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) in patients with respiratory failure due to Critical COVID-19.

The study showed that patients who were treated with the maximal standard of care plus ZYESAMI benefited significantly from the treatment, compared to those treated with placebo plus maximal standard of care. If authorized for use, ZYESAMI would be the first drug indicated specifically for COVID-19 patients who are critically ill with respiratory failure.

...

Quote:
"The study has not yet determined results for the stated primary endpoint of recovery from respiratory failure."


Preliminary Study Results:

+ Primary endpoint = resolution of respiratory failure within 28 days after treatment started. [On-going assessment].

+ Secondary endpoints = (A) patient survival [Success], (B) time to ICU discharge [Success], (C) time to hospital discharge [Success], (D) time to return to NIAID score of 6-8 [Data unavailable], and (E) safety [Success].

+ Standard of care (SOC) treatments including Remdesivir, anti-cytokine drugs, steroids, and anticoagulants.
A total of 138 patients (91 ZYESAMI, 47 SOC) survived through Day 28. Ninety-six patients (65 ZYESAMI, 31 SOC) were discharged from the hospital by Day 28.



Upcoming:

+ Will discuss with FDA submission of an Emergency Use Authorization (EUA).

+ Launched a phase 2/3 trial to explore its inhaled use in patients who are not yet in respiratory failure.

+ Further study of ZYESAMI's role in critical COVID-19 will be conducted under the BARDA and DOD Medical Countermeasures-funded I-SPY trial.

+ Signed a clinical trial agreement with another federal program the details of which will be announced shortly.

+ Will report on day 60 survival.

+ The first demonstration of clinically and statistically-significant benefit by any therapeutic agent in patients with COVID-19 respiratory failure in a randomized, double-blind, prospective trial.


https://www.biospace.com/article/releases/neu...-covid-19/

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 7

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 8

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 8

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 6

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading

Top 5 Most Recently Viewed Articles

Bellring Brands Achieves Record Stock High Amid Market Optimism

Updated Category News Views 178

Bellring Brands Achieves Record Stock High in Financial Milestone Bellring Brands LLC (BRBR) has made headlines recently as its stock reached an impressive milestone, hitting an all-time high of $62.76. This remarkable increase signals a surge in investor confidence, demonstrated by the stock's substantial 1-year change of 46.23%. The performance of Bellring Brands has...

Continue Reading
Celebrating Dr. Shelley Doumani-Semino's Lifetime Achievement

Updated Category News Views 216

Dr. Shelley Doumani-Semino Earns Pinnacle Lifetime Membership Renowned for her significant contributions to the field of addiction psychiatry, Dr. Shelley Doumani-Semino, MD, LFAPA, has been honored with the designation of Pinnacle Lifetime Member, as highlighted in The Inner Circle. This recognition celebrates her extensive work in addiction psychiatry and psychiatric...

Continue Reading
Arcus Biosciences Plans Conference Call for Q3 Financial Review

Updated Category News Views 40

Conference Call Announcement for Financial Results Arcus Biosciences (NYSE: RCUS), a forward-thinking clinical-stage biopharmaceutical company, has announced plans for a significant conference call. The focus will be on discussing its financial results for the third quarter, as well as updates on its product pipeline, which is crucial for its commitment to provide...

Continue Reading
CareDx Achieves Major Milestone as DOJ Closes Investigation

Updated Category News Views 148

CareDx Gains Confidence as Investigations Conclude Recently, CareDx, Inc. (NASDAQ: CDNA) celebrated a significant victory as BTIG reaffirmed its Buy rating, coupled with an ambitious $40 price target for the company's stocks. This optimistic outlook emerged right after the Department of Justice (DOJ) completed its investigation, finding no evidence of misconduct and...

Continue Reading
Indaptus Therapeutics CEO Engages at 2024 Maxim Summit

Updated Category News Views 93

Indaptus Therapeutics CEO to Speak at 2024 Maxim Healthcare Summit Indaptus Therapeutics, Inc. is set to make waves at the upcoming 2024 Maxim Healthcare Virtual Summit. The company's Chief Executive Officer, Jeffrey A. Meckler, will host a fireside chat during the event, which promises to be filled with insightful discussions about the company’s innovative approaches...

Continue Reading